<DOC>
	<DOC>NCT00837083</DOC>
	<brief_summary>This open label, non-interventional study is to show the efficacy of Crestor (rosuvastatin) in reduction of LDL-cholesterol and cardiovascular risk parameters in patients with hypercholesterolemia. Effectiveness is to be evaluated using the difference in LDL cholesterol level between the first and the second visit after 12 weeks.</brief_summary>
	<brief_title>Evaluation of CrestorÂ® (Rosuvastatin) in Daily Practice</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>a patient with hypercholesterolemia who has been prescribed Crestoraccording to physician's judgement, irrespective of the inclusion in the study. no treatment with any statin in the last 3 months hypersensitivity to rosuvastatin or any other ingredient of Crestor active liver disease, severe renal insufficiency myopathy or predisposing risk factors for myopathy/ rhabdomyolysis woman of childbearing potential and not using appropriate contraceptive measures, pregnancy or lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>hypercholesterolemia</keyword>
	<keyword>cholesterol</keyword>
	<keyword>LDL-cholesterol</keyword>
	<keyword>rosuvastatin</keyword>
	<keyword>Crestor</keyword>
</DOC>